Endoscopy 2012; 44(11): 993-997
DOI: 10.1055/s-0032-1325678
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Prevalence of buried Barrett’s metaplasia in patients before and after radiofrequency ablation


J. Yuan1, J. C. Hernandez2, S. K. Ratuapli2, K. C. Ruff2, G. De Petris3, D. M. Lam-Himlin3, G. E. Burdick2, R. Pannala2, F. C. Ramirez2, D. E. Fleischer2
  • 1Department of Internal Medicine, Banner Good Samaritan Medical Center, Phoenix, Arizona, USA
  • 2Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
  • 3Department of Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
Further Information

Publication History

Received: 23 August 2011

Accepted: 25 May 2012

Publication Date:
29 October 2012 (online)

Background and study aim: Radiofrequency ablation (RFA) to treat Barrett’s esophagus is increasingly accepted. Description of the etiology, natural history, and prevalence of buried Barrett’s metaplasia (BBM) following RFA is limited, although BBM continues to pose a clinical dilemma. We aimed to assess the prevalence, characteristics, and eradication rate of BBM in patients with both dysplastic and nondysplastic Barrett’s esophagus, treated with RFA and followed over time.

Patients and methods: The presence of Barrett’s esophagus, dysplasia, and BBM, before and after RFA, was assessed by two gastrointestinal pathologists in a retrospective chart review of patients who had undergone RFA at our center and had completed appropriate follow-up. 

Results: We identified 112 patients with completed treatment and no further planned RFA. In 108, no residual Barrett’s esophagus was seen after RFA; 4 patients with persistent Barrett’s tissue underwent surgery. Regarding BBM, 17 /112 patients (15.2 %) had evidence of BBM during evaluation. In 12 /17 (70.5 %) BBM was found during the RFA treatment, with 8 having previously undergone non-RFA therapy and RFA for Barrett’s esophagus and 4 having no previous intervention. In 5 /17 (29.4 %), BBM was seen only after RFA monotherapy. All 17 showed no evidence of BBM at final evaluation and were classified in the complete remission group (108 /112).

Conclusion: Both Barrett’s esophagus and BBM were completely eradicated in all patients with long-term follow-up after RFA. Almost half of the patients with BBM had a prior history of non-RFA therapy for Barrett’s esophagus compared with 26 % the non-BBM cohort. All patients with previously identified Barrett’s esophagus and BBM were completely cleared of disease at final follow-up.